What is Allrock Bio?
Allrock Bio operates as a clinical-stage biotechnology enterprise dedicated to the advancement of innovative therapies for cardiopulmonary and fibrotic diseases. The company's core value proposition centers on its lead candidate, ROC-101, a first-in-class, oral pan-ROCK inhibitor. This therapeutic agent is specifically engineered to address the significant unmet medical needs associated with pulmonary arterial hypertension and related life-threatening fibrotic disorders. By focusing on disease-modifying mechanisms, Allrock Bio distinguishes itself within the competitive biotech sector, utilizing a seasoned leadership team to bridge the gap between scientific discovery and clinical application. The firm's strategic focus on high-barrier-to-entry indications positions it as a specialized entity capable of delivering substantial value to both the medical community and the broader healthcare market.
How much funding has Allrock Bio raised?
Allrock Bio has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2025): $50M with participation from Westlake Village BioPartners and Versant Ventures
Key Investors in Allrock Bio
Westlake Village BioPartners
A life science venture capital firm focused on investing in world-class entrepreneurs to create innovative biotech companies, emphasizing hands-on support from ideation to commercial impact.
Versant Ventures
A prominent venture capital firm with over $5.5 billion under management, specializing in building and funding innovative biotechnology companies through extensive academic and scientific partnerships.
What's next for Allrock Bio?
Following this major enterprise-level funding, Allrock Bio is poised to scale its clinical operations and expand its research capabilities. The strategic roadmap involves prioritizing the advancement of ROC-101 through rigorous clinical trials, ensuring that the company meets the necessary regulatory benchmarks for future commercialization. Furthermore, the influx of capital will likely facilitate the expansion of the firm's internal scientific team and the enhancement of its laboratory infrastructure. As the company moves forward, the focus will remain on executing its development strategy while maintaining the agility required to navigate the complexities of the biotechnology regulatory environment. This phase of growth is critical for validating the efficacy of its pan-ROCK inhibitor platform and establishing a robust foundation for long-term therapeutic impact.
See full Allrock Bio company page
